Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Androgen Derivatives Improve Blood Counts and Elongate Telomere Length in Patients with Dyskeratosis Congenita

Martin Kirschner, MD, Monica Sofia Ventura Ferreira, PhD, Anne-Sophie Bouillon, MD, Marcin W. Wlodarski, MD PhD, Michaela Schwarz, MD, Stefan Balabanov, MD PhD, Stefan Wilop, MD, Steffen Koschmieder, MD, Jens P. Panse, MD, Tim H. Brümmendorf, MD, Fabian Beier, MD

Blood (2018) 132 (Supplement 1): 2585.

https://doi.org/10.1182/blood-2018-99-118197

Published: 2018

Journal Articles

Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg

Blood (2012) 120 (21): 302.

https://doi.org/10.1182/blood.V120.21.302.302

Published: 2012

Journal Articles

Telomere Elongation In Vivo and Clinical Response Upon Androgen Treatment in a Patient with Aplastic Anemia and a Heterozygous hTERT Gene Mutation,

Tim H Brümmendorf, Patrick Ziegler, PhD, Jamil Akkad, MD, Ute Brassat, PhD, Lucia Vankann, Jens Panse, MD, Stefan Wilop, MD, Stefan Balabanov, MD, PhD, Klaus Schwarz, MD, Uwe M. Martens, MD, PhD, Hubert Schrezenmeier, MD

Blood (2011) 118 (21): 3427.

https://doi.org/10.1182/blood.V118.21.3427.3427

Published: 2011

Journal Articles

Combination Therapy of Small Molecule Inhibitor PHA-739358 and Tyrosine Kinase Inhibitor Imatinib Yields Synergistic Antiproliferative Effects and Suppresses Emergence of Resistance of Chronic Myeloid Leukemia in Vitro

Stefan Balabanov, MD/PhD, Artur Gontarewicz, MD, Gunhild Keller, MD, Jürgen Moll, PhD, Carsten Bokemeyer, MD, Tessa L Holyoake, MD/PhD, Tim H. Brummendorf, MD

Blood (2008) 112 (11): 3227.

https://doi.org/10.1182/blood.V112.11.3227.3227

Published: 2008

Journal Articles

Identification of Novel Biomarkers for Prediction of Response to Tyrosine Kinase Inhibitors (TKIs) by Proteomic Profiling of Imatinib as Well as 2 nd and 3 rd Generation TKIs in Vitro

Stefan Balabanov, MD/PhD, Thoma Wilhelm, PhD, Simone Venz, PhD, Christine Barret, Gunhild Keller, MD, Mirja Bernhardt, Artur Gontarewicz, MD, Melanie Braig, PhD, Reinhard Walther, PhD, Tim H. Brummendorf, MD

Blood (2008) 112 (11): 336.

https://doi.org/10.1182/blood.V112.11.336.336

Published: 2008

Journal Articles

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Stefan Balabanov, MD, PhD, Artur Gontarewicz, MD, Patrick Ziegler, PhD, Ulrike Hartmann, PhD, Mhairi Copland, MD, Ute Brassat, Ilona Hauber, PhD, Lothar Kanz, MD, Carsten Bokemeyer, MD, Alfred Nordheim, PhD, Joachim Hauber, PhD, Tessa L. Holyoake, MD, Tim H. Brummendorf, MD

Blood (2006) 108 (11): 1379.

https://doi.org/10.1182/blood.V108.11.1379.1379

Published: 2006

Journal Articles

Characterization of Bcr-Abl Positive Leukemic Cells under Long-Term In Vitro Treatment with Telomerase Inhibitor BIBR1532.

Ute Brassat, Stefan Balabanov, MD/PhD, Ulrike Hartmann, PhD, Daniel Rössler, Kerstin Borgmann, PhD, Judith Dierlamm, MD/PhD, Tim H. Brummendorf, MD

Blood (2006) 108 (11): 2185.

https://doi.org/10.1182/blood.V108.11.2185.2185

Published: 2006

Journal Articles

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Stefan Balabanov, MD, PhD, Patrick Ziegler, PhD, Ulricke Hartmann, Winfried Kammer, PhD, Mhairi Copland, MD, Martin Priemer, Thomas Wilhelm, Carsten Bokemeyer, MD, Lothar Kanz, MD, Tessa Holyoake, MD, Alfred Nordheim, PhD, Tim Bruemmendorf, MD

Blood (2005) 106 (11): 1997.

https://doi.org/10.1182/blood.V106.11.1997.1997

Published: 2005

Journal Articles

Identification of BCR-ABL Dependent Gene Regulation by Using a Phosphoproteomics Approach.

Patrick Ziegler, PhD, Stefan Balabanov, MD PhD, Ulrike Hartmann, Winfried Kammer Kammer, PhD, Alfred Nordheim, PhD, Tim H. Brummendorf, MD

Blood (2004) 104 (11): 2944.

https://doi.org/10.1182/blood.V104.11.2944.2944

Published: 2004

Journal Articles

Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach.

Stefan Balabanov, MD PhD, Ulrike Hartmann, Winfried Kammer, PhD, Patrick Ziegler, PhD, Martin Priemer, Gerold Schwarz, Lothar Kanz, MD, Alfred Nordheim, PhD, Tim H. Brummendorf, MD

Blood (2004) 104 (11): 2957.

https://doi.org/10.1182/blood.V104.11.2957.2957

Published: 2004

Journal Articles

Proaerolysin Multi Color Flow-Fish Reveals Shortened Telomere Length in GPI− as Compared to GPI+ Granulocytes from Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).

Fabian Beier, Stefan Balabanov, MD, PhD, Tom Buckley, PhD, M. Rojewski, T. Becker, MD, Lothar Kanz, MD, Hubert Schrezenmeier, MD, Tim H. Brummendorf, MD

Blood (2004) 104 (11): 171.

https://doi.org/10.1182/blood.V104.11.171.171

Published: 2004

NARROW

Androgen Derivatives Improve Blood Counts and Elongate Telomere Length in Patients with Dyskeratosis Congenita

Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg

Telomere Elongation In Vivo and Clinical Response Upon Androgen Treatment in a Patient with Aplastic Anemia and a Heterozygous hTERT Gene Mutation,

Combination Therapy of Small Molecule Inhibitor PHA-739358 and Tyrosine Kinase Inhibitor Imatinib Yields Synergistic Antiproliferative Effects and Suppresses Emergence of Resistance of Chronic Myeloid Leukemia in Vitro

Identification of Novel Biomarkers for Prediction of Response to Tyrosine Kinase Inhibitors (TKIs) by Proteomic Profiling of Imatinib as Well as 2 nd and 3 rd Generation TKIs in Vitro

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Characterization of Bcr-Abl Positive Leukemic Cells under Long-Term In Vitro Treatment with Telomerase Inhibitor BIBR1532.

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Identification of BCR-ABL Dependent Gene Regulation by Using a Phosphoproteomics Approach.

Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach.

Proaerolysin Multi Color Flow-Fish Reveals Shortened Telomere Length in GPI− as Compared to GPI+ Granulocytes from Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only